LTR Pharma

Results of 2025 Annual General Meeting

24 October 2025

LTR Pharma Limited (ASX:LTP) ("LTR Pharma" or "the "**Company")** is pleased to advise that shareholders of the Company passed all Resolutions by poll at the Annual General Meeting held today at 2:00pm (AEST).

In accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act, enclosed is a summary of the resolutions considered, the proxies received and the outcomes of voting for each respective resolution at the 2025 Annual General Meeting.

With regard to Resolution 1 - Adoption of Remuneration Report, the Resolution was passed with more than 75% votes in favour of the resolution.

- ENDS –

This announcement has been approved for release by the Company Secretary.

About LTR Pharma

LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies for significant unmet medical needs through its proprietary intranasal drug delivery platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the US and other key markets.

LTR's lead products, SPONTAN® and ROXUS®, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW®, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.

Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.

For further information please contact:

Media enquiries Haley Chartres haley@hck.digital	Investor enquiries Peter McLennan investors@ltrpharma.com

Disclosure of Proxy Votes

LTR Pharma Limited

Annual General Meeting

Friday, 24 October 2025

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**Total Number of Proxy Votes exercisable by proxies validly appointed**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 Adoption of Remuneration Report	P	4,234,321	4,029,240 95.16%	165,201 3.90%	26,500	39,880 0.94%	4,114,856 96.14%	165,201 3.86%	26,500	-
2 Re-election of Maja McGuire as Director	P	55,912,310	55,810,095 99.82%	72,335 0.13%	39,902	29,880 0.05%	58,609,838 99.88%	72,335 0.12%	39,902	Carried
3 Ratification of Prior Issue of Fully Paid Ordinary Shares	P	53,814,918	53,622,290 99.64%	152,748 0.28%	80,527	39,880 0.07%	56,432,033 99.73%	152,748 0.27%	80,527	Carried
4 Ratification of Prior Issue of Fully Paid Ordinary Shares	P	53,814,918	53,639,801 99.67%	135,237 0.25%	80,527	39,880 0.07%	56,449,544 99.76%	135,237 0.24%	80,527	Carried
5 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	55,949,212	55,735,644 99.62%	173,688 0.31%	3,000	39,880 0.07%	58,545,387 99.70%	173,688 0.30%	3,000	Carried
6 Adoption of Employee Incentive Plan	P	4,127,325	3,822,599 92.62%	264,846 6.42%	133,496	39,880 0.97%	4,606,215 94.56%	264,846 5.44%	133,496	Carried
7 Approval of Issue of Options to Lee Rodne, Director of the Company	P	4,253,570	3,534,812 83.10%	674,611 15.86%	7,251	44,147 1.04%	4,668,679 87.37%	674,611 12.63%	7,251	Carried
8 Approval of Issue of Options to Julian Chick, Director of the Company	P	55,854,961	55,050,116 98.56%	750,698 1.34%	97,251	54,147 0.10%	57,065,634 98.70%	750,698 1.30%	97,251	Carried

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**Total Number of Proxy Votes exercisable by proxies validly appointed**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
9 Approval of Issue of Options to Maja McGuire, Director of the Company	P	55,854,961	55,000,116 98.47%	800,698 1.43%	97,251	54,147 0.10%	57,588,634 98.63%	800,698 1.37%	97,251	Carried
10 Approval of Issue of Options to Alpine Capital Pty Limited	P	55,854,961	55,187,546 98.81%	627,535 1.12%	97,251	39,880 0.07%	57,997,289 98.93%	627,535 1.07%	97,251	Carried